The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

PubChem17487     1,3-thiazolidine-2,4-dione

Synonyms: ARONIS23865, CHEMBL85398, NSC-6745, ACMC-1ANE1, AG-B-76923, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Thiazolidinedione


Psychiatry related information on Thiazolidinedione

  • We thus determined whether the thiazolidinedione pioglitazone reverses the decrease in cerebral glucose utilisation (CGU) in a model of brain metabolic deficiency related to Alzheimer's disease [6].
  • Thiazolidinediones, in particular, have received much attention, not only for the well documented hepatotoxicity of troglitazone that led to its removal from the market in 2000, but also for the emerging data that support the beneficial effects of the thiazolidinedione class of drugs on beta-cell rejuvenation and cardiovascular risk reduction [7].

High impact information on Thiazolidinedione


Chemical compound and disease context of Thiazolidinedione


Biological context of Thiazolidinedione


Anatomical context of Thiazolidinedione


Associations of Thiazolidinedione with other chemical compounds

  • Troglitazone (1 microM), a member of the thiazolidinedione class, produced a near complete inhibition of both bFGF-induced DNA synthesis as measured by bromodeoxyuridine incorporation (6.5+/-3.9 vs. 17.6+/-4.3% cells labeled, P < 0.05) and c-fos induction [28].
  • 5. Maternally administered pioglitazone, a thiazolidinedione compound, resolved these molecular defects of Pkd1(-/-) [29].
  • The effect of fibrates is specific for peroxisome proliferator-activated receptor-alpha (PPARalpha) because a high-affinity ligand for PPARgamma, the thiazolidinedione BRL 49653, lowered triglyceride levels, but was unable to suppress fibrinogen expression [30].
  • Thiazolidinedione treatment enhances insulin effects on protein kinase C-zeta /lambda activation and glucose transport in adipocytes of nondiabetic and Goto-Kakizaki type II diabetic rats [31].
  • AMP-activated protein kinase (AMPK) is a key molecular regulator of cellular metabolism, and its activity is induced by both metformin and thiazolidinedione antidiabetic medications [32].

Gene context of Thiazolidinedione


Analytical, diagnostic and therapeutic context of Thiazolidinedione


  1. Liver enzyme monitoring in patients treated with troglitazone. Graham, D.J., Drinkard, C.R., Shatin, D., Tsong, Y., Burgess, M.J. JAMA (2001) [Pubmed]
  2. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Young, P.W., Cawthorne, M.A., Coyle, P.J., Holder, J.C., Holman, G.D., Kozka, I.J., Kirkham, D.M., Lister, C.A., Smith, S.A. Diabetes (1995) [Pubmed]
  3. Effect of troglitazone on leptin production. Studies in vitro and in human subjects. Nolan, J.J., Olefsky, J.M., Nyce, M.R., Considine, R.V., Caro, J.F. Diabetes (1996) [Pubmed]
  4. Inhibition of LDL oxidation in vitro but not ex vivo by troglitazone. Crawford, R.S., Mudaliar, S.R., Henry, R.R., Chait, A. Diabetes (1999) [Pubmed]
  5. Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. Roberts, A.W., Thomas, A., Rees, A., Evans, M. Curr. Opin. Lipidol. (2003) [Pubmed]
  6. Pioglitazone does not increase cerebral glucose utilisation in a murine model of Alzheimer's disease and decreases it in wild-type mice. Galea, E., Feinstein, D.L., Lacombe, P. Diabetologia (2006) [Pubmed]
  7. Thiazolidinediones and insulin: rationale for use and role of combination therapy in type 2 diabetes mellitus. Huang, A., Raskin, P. Treatments in endocrinology. (2005) [Pubmed]
  8. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Forman, B.M., Tontonoz, P., Chen, J., Brun, R.P., Spiegelman, B.M., Evans, R.M. Cell (1995) [Pubmed]
  9. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Moore, K.J., Rosen, E.D., Fitzgerald, M.L., Randow, F., Andersson, L.P., Altshuler, D., Milstone, D.S., Mortensen, R.M., Spiegelman, B.M., Freeman, M.W. Nat. Med. (2001) [Pubmed]
  10. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Kroll, T.G., Sarraf, P., Pecciarini, L., Chen, C.J., Mueller, E., Spiegelman, B.M., Fletcher, J.A. Science (2000) [Pubmed]
  11. Terminal differentiation of human breast cancer through PPAR gamma. Mueller, E., Sarraf, P., Tontonoz, P., Evans, R.M., Martin, K.J., Zhang, M., Fletcher, C., Singer, S., Spiegelman, B.M. Mol. Cell (1998) [Pubmed]
  12. Search for the preadipocyte progenitor cell. Hausman, G.J., Hausman, D.B. J. Clin. Invest. (2006) [Pubmed]
  13. Pilot Study of Rosiglitazone Therapy in Women with Breast Cancer: Effects of Short-term Therapy on Tumor Tissue and Serum Markers. Yee, L.D., Williams, N., Wen, P., Young, D.C., Lester, J., Johnson, M.V., Farrar, W.B., Walker, M.J., Povoski, S.P., Suster, S., Eng, C. Clin. Cancer Res. (2007) [Pubmed]
  14. Putative activation of the peroxisome proliferator-activated receptor gamma impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells. Schoppee, P.D., Garmey, J.C., Veldhuis, J.D. Biol. Reprod. (2002) [Pubmed]
  15. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Roberts, V.L., Stewart, J., Issa, M., Lake, B., Melis, R. Clinical therapeutics. (2005) [Pubmed]
  16. Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. Lebovic, D.I., Kir, M., Casey, C.L. Fertil. Steril. (2004) [Pubmed]
  17. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Cuzzocrea, S., Pisano, B., Dugo, L., Ianaro, A., Maffia, P., Patel, N.S., Di Paola, R., Ialenti, A., Genovese, T., Chatterjee, P.K., Di Rosa, M., Caputi, A.P., Thiemermann, C. Eur. J. Pharmacol. (2004) [Pubmed]
  18. Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. Guan, H.P., Ishizuka, T., Chui, P.C., Lehrke, M., Lazar, M.A. Genes Dev. (2005) [Pubmed]
  19. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. Vidal-Puig, A.J., Considine, R.V., Jimenez-Liñan, M., Werman, A., Pories, W.J., Caro, J.F., Flier, J.S. J. Clin. Invest. (1997) [Pubmed]
  20. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. De Vos, P., Lefebvre, A.M., Miller, S.G., Guerre-Millo, M., Wong, K., Saladin, R., Hamann, L.G., Staels, B., Briggs, M.R., Auwerx, J. J. Clin. Invest. (1996) [Pubmed]
  21. Insulinotropic meglitinide analogues. Dornhorst, A. Lancet (2001) [Pubmed]
  22. Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. Lu, M., Kwan, T., Yu, C., Chen, F., Freedman, B., Schafer, J.M., Lee, E.J., Jameson, J.L., Jordan, V.C., Cryns, V.L. J. Biol. Chem. (2005) [Pubmed]
  23. IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Bendixen, A.C., Shevde, N.K., Dienger, K.M., Willson, T.M., Funk, C.D., Pike, J.W. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  24. Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes. Digby, J.E., Montague, C.T., Sewter, C.P., Sanders, L., Wilkison, W.O., O'Rahilly, S., Prins, J.B. Diabetes (1998) [Pubmed]
  25. Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression. Brunmair, B., Gras, F., Neschen, S., Roden, M., Wagner, L., Waldhäusl, W., Fürnsinn, C. Diabetes (2001) [Pubmed]
  26. Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. Zhang, B., Berger, J., Zhou, G., Elbrecht, A., Biswas, S., White-Carrington, S., Szalkowski, D., Moller, D.E. J. Biol. Chem. (1996) [Pubmed]
  27. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. Gurnell, M., Wentworth, J.M., Agostini, M., Adams, M., Collingwood, T.N., Provenzano, C., Browne, P.O., Rajanayagam, O., Burris, T.P., Schwabe, J.W., Lazar, M.A., Chatterjee, V.K. J. Biol. Chem. (2000) [Pubmed]
  28. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. Law, R.E., Meehan, W.P., Xi, X.P., Graf, K., Wuthrich, D.A., Coats, W., Faxon, D., Hsueh, W.A. J. Clin. Invest. (1996) [Pubmed]
  29. Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Muto, S., Aiba, A., Saito, Y., Nakao, K., Nakamura, K., Tomita, K., Kitamura, T., Kurabayashi, M., Nagai, R., Higashihara, E., Harris, P.C., Katsuki, M., Horie, S. Hum. Mol. Genet. (2002) [Pubmed]
  30. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Kockx, M., Gervois, P.P., Poulain, P., Derudas, B., Peters, J.M., Gonzalez, F.J., Princen, H.M., Kooistra, T., Staels, B. Blood (1999) [Pubmed]
  31. Thiazolidinedione treatment enhances insulin effects on protein kinase C-zeta /lambda activation and glucose transport in adipocytes of nondiabetic and Goto-Kakizaki type II diabetic rats. Kanoh, Y., Bandyopadhyay, G., Sajan, M.P., Standaert, M.L., Farese, R.V. J. Biol. Chem. (2000) [Pubmed]
  32. Haplotype structures and large-scale association testing of the 5' AMP-activated protein kinase genes PRKAA2, PRKAB1, and PRKAB1 with type 2 diabetes. Sun, M.W., Lee, J.Y., de Bakker, P.I., Burtt, N.P., Almgren, P., Råstam, L., Tuomi, T., Gaudet, D., Daly, M.J., Hirschhorn, J.N., Altshuler, D., Groop, L., Florez, J.C. Diabetes (2006) [Pubmed]
  33. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Kallen, C.B., Lazar, M.A. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  34. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Kim, J.B., Wright, H.M., Wright, M., Spiegelman, B.M. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  35. Essential role of insulin receptor substrate 1 in differentiation of brown adipocytes. Fasshauer, M., Klein, J., Kriauciunas, K.M., Ueki, K., Benito, M., Kahn, C.R. Mol. Cell. Biol. (2001) [Pubmed]
  36. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. Adams, M., Reginato, M.J., Shao, D., Lazar, M.A., Chatterjee, V.K. J. Biol. Chem. (1997) [Pubmed]
  37. Lipotoxic diseases. Unger, R.H. Annu. Rev. Med. (2002) [Pubmed]
  38. Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs. Xu, Y., Lu, L., Greyson, C., Lee, J., Gen, M., Kinugawa, K., Long, C.S., Schwartz, G.G. Diabetes (2003) [Pubmed]
  39. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Lebovitz, H.E., Kreider, M., Freed, M.I. Diabetes Care (2002) [Pubmed]
  40. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Hsueh, W.A., Jackson, S., Law, R.E. Diabetes Care (2001) [Pubmed]
  41. Identification of a functional peroxisome proliferator-activated receptor responsive element within the murine perilipin gene. Nagai, S., Shimizu, C., Umetsu, M., Taniguchi, S., Endo, M., Miyoshi, H., Yoshioka, N., Kubo, M., Koike, T. Endocrinology (2004) [Pubmed]
WikiGenes - Universities